Zobrazeno 1 - 10
of 13
pro vyhledávání: '"David Cieremans"'
Autor:
Meghna S. Trivedi, Melissa K. Accordino, Fabio M. Iwamoto, Deanna Fisher, Lan Huynh, Kathleen Fenn, Julie Ann Mayer, Kevin Kalinsky, Dawn L. Hershman, Julia E. McGuinness, David Cieremans, Edgar V. Sales, Mary Welch, Margaux Wooster, Robbie Schultz, Shing Lee, Lauren Franks, Teri N. Kreisl, Andrew B. Lassman, Katherine D. Crew, Veena M. Singh, Aya Haggiagi
Publikováno v:
Clin Breast Cancer
Diagnosis of LM is limited by low sensitivity of cerebrospinal fluid (CSF) cytopathology. Detecting tumor cells in CSF (CSF-TCs) might be more sensitive. We evaluated if CNSide (CNSide), a novel assay for tumor cell detection in CSF, can detect CSF-T
Autor:
David Cieremans, Nishanth Muthusamy, Vivek Singh, Joshua C. Rozell, Vinay Aggarwal, Ran Schwarzkopf
Publikováno v:
European Journal of Orthopaedic Surgery & Traumatology.
Publikováno v:
JAAOS: Global Research and Reviews. 7
Publikováno v:
Archives of orthopaedic and trauma surgery.
Optimization of patient outcomes and identification of factors to improve the surgical workflow are increasingly important. Operating room time is one modifiable factor that leads to greater hospital efficiency as well as improved outcomes such as sh
Autor:
Thai H. Tran, Jennifer Bordeaux, Shabnam Tangri, J. M. Santos, Ju Young Kim, Ariana Valencia, David Cieremans, Christine Vaupel, Naveen Dakappagari, Fabio M. Iwamoto
Introduction: PD-1 inhibitors have shown limited efficacy in glioblastoma due to microenvironment immunosuppression and low tumor mutational burden. In GBM, PD-L1 expression is not a predictive marker for response to PD-1 or PD-L1 inhibitors. Multipl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93996c69a0cd4223e03903afbe703b42
https://doi.org/10.21203/rs.3.rs-341251/v2
https://doi.org/10.21203/rs.3.rs-341251/v2
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
Autor:
Víctor A. Arrieta, Bin Zhang, Daniel J. Brat, Xiaoyang Ling, Daniel Zhang, Jinzhou Yuan, David Cieremans, Timothy F. Cloughesy, Lee Cooper, Peter Canoll, Robert M. Prins, Matthew McCord, Roger Stupp, Christina Amidei, Adam M. Sonabend, Gerson Rothschild, Catalina Lee-Chang, Li Chen, Cynthia Kassab, Pavan S. Upadhyayula, Jonathan T. Yamaguchi, Wenting Zhao, Dinesh Jaishankar, Kirsten Bell Burdett, Brice Laffleur, Amy B. Heimberger, Seong Jae Kang, Hui Zhang, Uttiya Basu, Andrew X. Chen, J. Robert Kane, Craig Horbinski, Peter A. Sims, Crismita Dmello, Jared K. Burks, Joseph Shilati, Jeffrey N. Bruce, Fabio M. Iwamoto, Raul Rabadan, Andrew Gould, Rimas V. Lukas, Junfei Zhao
Publikováno v:
Nature Cancer
Nature Cancer, Nature Research 2021, 2 (12), pp.1372-+. ⟨10.1038/s43018-021-00260-2⟩
Nat Cancer
Nature Cancer, 2021, 2 (12), pp.1372-+. ⟨10.1038/s43018-021-00260-2⟩
Nature Cancer, Nature Research 2021, 2 (12), pp.1372-+. ⟨10.1038/s43018-021-00260-2⟩
Nat Cancer
Nature Cancer, 2021, 2 (12), pp.1372-+. ⟨10.1038/s43018-021-00260-2⟩
International audience; In two cohorts of patients with glioblastoma who received anti-PD-1, Sonabend and colleagues show that ERK1/2 phosphorylation, detected by immunohistochemistry, provides a biomarker for MAPK/ERK pathway activity and better sur
Autor:
Veena M. Singh, Robbie Schultz, Melissa Kate Accordino, Deanna Fisher, Margaux Wooster, Julia E. McGuinness, Lan Huynh, Kathleen Fenn, Aya Haggiagi, Teri Kreisl, Julie Ann Mayer, Fabio M. Iwamoto, Andrew B. Lassman, Edgar V. Sales, Meghna S. Trivedi, Katherine D. Crew, Mary Welch, Shing Lee, Kevin Kalinsky, Lauren Franks, Dawn L. Hershman, David Cieremans
Introduction: Diagnosis of leptomeningeal metastasis (LM) is limited by low sensitivity of cerebrospinal fluid (CSF) cytopathology. Detecting circulating tumor cells (CTCs) in CSF might be more sensitive. We evaluated if TargetSelector™ (TS), a nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69da7cc716c574bcab3e4db9d540a32d
https://doi.org/10.21203/rs.3.rs-206232/v1
https://doi.org/10.21203/rs.3.rs-206232/v1
Autor:
Jennifer Bordeaux, Naveen Dakappagari, Thai H. Tran, David Cieremans, J. M. Santos, Ju Young Kim, Shabnam Tangri, Fabio M. Iwamoto, Christine Vaupel, Ariana Valencia
Publikováno v:
Neuro Oncol
BACKGROUND PD-1 inhibitors have shown limited efficacy in glioblastoma (GBM) due to microenvironment immunosuppression and low tumor mutational burden. In GBM, PD-L1 expression is not a predictive marker for response to PD-1 or PD-L1 inhibitors. Mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd00b74e6be89d9f511ed11eaa6169e
https://europepmc.org/articles/PMC7650383/
https://europepmc.org/articles/PMC7650383/
Autor:
Víctor A. Arrieta, Andrew X. Chen, J. Robert Kane, Seong Jae Kang, Cynthia Kassab, Crismita Dmello, Junfei Zhao, Kirsten B. Burdett, Pavan S. Upadhyayula, Catalina Lee-Chang, Joseph Shilati, Dinesh Jaishankar, Li Chen, Andrew Gould, Daniel Zhang, Jinzhou Yuan, Wenting Zhao, Xiaoyang Ling, Jared K. Burks, Brice Laffleur, Christina Amidei, Jeffrey N. Bruce, Rimas V. Lukas, Jonathan T. Yamaguchi, David Cieremans, Gerson Rothschild, Uttiya Basu, Matthew McCord, Daniel J. Brat, Hui Zhang, Lee A. D. Cooper, Bin Zhang, Peter Sims, Tim F. Cloughesy, Robert Prins, Peter Canoll, Roger Stupp, Amy B. Heimberger, Craig Horbinski, Fabio M. Iwamoto, Raul Rabadan, Adam M. Sonabend
Publikováno v:
Nature Cancer. 3:373-373
Autor:
Raul Rabadan, Jeffrey N. Bruce, Peter A. Sims, Daniel J. Brat, Matthew R McCord, Pavan S. Upadhyayula, Andrew Gould, Hui Zhang, Gerson Rothschild, Xiaoyang Ling, Kirsten Bell Burdett, Fabio M. Iwamoto, Lee Cooper, Joseph Shilati, Rimas V. Lukas, Junfei Zhao, Cynthia Kassab, Uttiya Basu, Brice Laffleur, Wenting Zhao, Dinesh Jaishankar, Li Chen, Daniel Zhang, Peter Canoll, Robert M. Prins, Amy B. Heimberger, J. Robert Kane, Timothy F. Cloughesy, Catalina Chang, Crismita Dmello, Jared K. Burks, Craig Horbinski, Jinzhou Yuan, David Cieremans, Jonathan T. Yamaguchi, Andrew X. Chen, Roger Stupp, Christina Amidei, Víctor A. Arrieta, Bin Zhang, Adam M. Sonabend, Seong Jae Kang
Publikováno v:
Neuro-Oncology. 23:vi17-vi17
PD-1 checkpoint inhibition has led to remarkable clinical responses in several cancer types. Whereas PD-1 blockade has not shown an overall survival (OS) benefit for glioblastoma (GBM) patients, a subset of them exhibit long-term responses to this im